HLS Therapeutics (TSE:HLS) Shares Down 1.5% – Time to Sell?

HLS Therapeutics Inc. (TSE:HLS)’s share price dropped 1.5% on Wednesday . The company traded as low as C$5.33 and last traded at C$5.40. Approximately 7,701 shares traded hands during mid-day trading, a decline of 44% from the average daily volume of 13,810 shares. The stock had previously closed at C$5.48.

Wall Street Analyst Weigh In

Separately, Raymond James Financial raised shares of HLS Therapeutics from a “hold” rating to a “moderate buy” rating and increased their price objective for the stock from C$5.00 to C$6.00 in a research report on Thursday, August 21st. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of C$5.00.

HLS Therapeutics Trading Down 1.5%

The firm has a market capitalization of C$169.53 million, a PE ratio of -11.25 and a beta of 0.49. The stock’s 50-day moving average price is C$5.53 and its 200 day moving average price is C$5.05. The company has a debt-to-equity ratio of 86.50, a current ratio of 1.56 and a quick ratio of 1.01.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.